Table 1 HLA-B*1502 genotyping of CBZ-induced SJS/TEN patients

Patient no. / Age/sex / Ethnicity / Province / HLA-B*1502
1 / 44/F / Han Chinese / Anhui / N
2 / 48/M / Han Chinese / Jiangsu / P
3 / 31/F / Han Chinese / Jiangsu / P
4 / 50/M / Han Chinese / Jiangsu / P
5 / 65/F / Han Chinese / Jiangsu / P
6 / 37/M / Han Chinese / Liaoning / P
7 / 45/M / Han Chinese / Jiangsu / P
8 / 50/F / Han Chinese / Jiangsu / P
9 / 23/F / Han Chinese / Jiangsu / P
10 / 42/F / Han Chinese / Jiangsu / P
11 / 67/F / Han Chinese / Jiangsu / P
12 / 37/F / Han Chinese / Jiangsu / P
13 / 53/F / Han Chinese / Jiangsu / P
14 / 27/F / Han Chinese / Jiangsu / P
15 / 8/F / Han Chinese / Liaoning / P
16 / 12/F / Han Chinese / Liaoning / P
17 / 5/M / Han Chinese / Liaoning / P
aPatient
no. / Phenotype / Days from first drug exposure to diagnosis of SCR / Indication for use / bExanthem(%)/blister or detachment(%) / Mucous membrane erosion, number and sites / Systemic manifestations
1 / SJS / 21 / Neuralgia / 70-80/<10 / (+) 2: Oral, genital / Leukocytosis, fever, LFI
2 / SJS / 14 / Symptomatic epilepsy / 80-90/<10 / (+)1: Oral / Leukocytosis, fever, RFI
3 / SJS / 14 / Nervous tinnitus / 80-90/<10 / (+)1: Oral / Leukocytosis,
fever
4 / SJS / 23 / Neuralgia / 70-80/<10 / (+) 2: Oral, eyes / Leukocytosis, fever, LFI
5 / SJS/TEN / 12 / Trigeminal neuralgia / >90/20-30 / (+) 2: Oral, eyes / Leukocytosis, fever, LFI
6 / TEN / 13 / Trigeminal neuralgia / >90/>30 / (+) 2: Oral, eyes / Leukocytosis, fever, LFI
7 / SJS / 14 / Trigeminal neuralgia / 70-80/<10 / (+) 2: Oral, eyes / Fever
8 / SJS/TEN / 18 / Neuralgia / 80-90/<20-30 / (+) 2: Oral, genital / Leukocytosis,
fever
9 / SJS / 14 / Diabetes inspidus / 80-90/<10 / (+)3: Oral, eyes, genital / Fever
10 / SJS/TEN / 12 / Neuralgia / >90/20-30 / (+) 3:Oral, eyes, genital / Fever, LFI
11 / TEN / 14 / Neuralgia / 80-90/>30 / (+)3: Oral, eyes, genital / Leukocytosis, fever, LFI
12 / SJS / 13 / Sudden deafness / 80-90/<10 / (+) 2: Oral, eyes / Leukocytosis, fever, LFI
13 / SJS / 20 / Neuralgia / 80-90/<10 / (+) 2: Oral, eyes / Leukocytosis,
fever
14 / SJS / 17 / Epilepsy / 70-80/<10 / (+) 2: Oral, eyes / Fever, LFI
15 / SJS/TEN / 7 / Epilepsy / >90/10-20 / (+) 2: Oral, eyes / Fever
16 / TEN / 6 / Epilepsy / >90/>30 / (+) 2: Oral, eyes / Fever
17 / TEN / 7 / Epilepsy / >90/NA / (+)3: Oral, eyes, genital / Fever
Severe cutaneous reaction (SCR), Stevens–Johnson syndrome (SJS), Toxic epidermal necrolysis (TEN), liver function impairment (LFI), renal function impairment (RFI). NA, data not available
aNumber assigned to the patients by chronological order of recruitment.
bExanthema, erythematous or purpuric macules/papules; blister or detachment, extent of blisters or epidermal detachment; both exanthema and blister/detachment were expressed as % of total body surface area.

Table 2 Medication usage and clinical characteristics of patients with CBZ-induced SJS/TEN